RWC-340B on the Hill
On Monday, December 10, RWC-340B members spent the day on Capitol Hill advocating for the protection of the 340B program for Ryan White grantees and sub-grantees. Participants met with their…
HRSA to Begin Publishing 340B Ceiling Prices in 2019
Today, HRSA announced that it will begin publishing 340B ceiling prices starting April 1, 2019. HRSA will collect manufacturer pricing data on a quarterly basis and use the data to…
HHS Finalizes Manufacturer CMP and Penny Pricing Rule Effective January 1, 2019
Earlier today, HHS published a final rule to implement the 340B Ceiling Price and Manufacturer Civil Monetary Penalties Rule (CMP Rule) on January 1, 2019. The Affordable Care Act (ACA)…
HRSA Reporting on Services Funded Through Program Income
On October 29th, HRSA issued a notice that Ryan White Clinics will be required to report client-level data on patients whose services are funded through program income, starting with the…
HAB Revises Policy on Allowable Uses of Ryan White Grant Funds
On October 22, HAB revised its Policy Clarification Notice (PCN) 16-02, Ryan White HIV/AIDS Program Services: Eligible Individuals & Allowable Uses of Funds, which was originally released in 2016. PCN…
RWC-340B Leaders Meet with HRSA Administrator and Key HHS Staff
On October 29, 2018, RWC-340B leaders met with George Sigounas, M.S., Ph.D., the HRSA Administrator, and Beth Nelson, HHS Health Policy Advisor, to advocate to preserve and protect the 340B…
Proposed Rule Would Require Drug Manufacturers to Disclose Prices in TV Advertisements
On Monday, Health and Human Services Secretary Alex Azar announced a proposed rule that would require pharmaceutical manufacturers to disclose wholesale acquisition cost (“WAC”) prices in direct-to-consumer TV advertisements for…
New Legislation to Fight Opioid Epidemic Clears Congress, President Expected to Sign
On Wednesday, October 3, the U.S. Senate approved H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (“SUPPORT”) for Patients and Communities Act, by a vote of…
Gilead Will Begin Marketing Lower Cost Hepatitis C Drugs in January
Gilead Sciences Inc. announced that it would begin selling generic versions of the company’s two leading treatments for hepatitis C at substantially reduced prices. The generic versions of Epclusa and…
Hospital Groups File Lawsuit Challenging CMP Rule Delay
Yesterday, four national hospital groups and three hospital systems filed a lawsuit against HHS over the continued delay of the implementation date of the 340B Ceiling Price and Manufacturer Civil…